• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 69
  • 24
  • 13
  • 7
  • 6
  • 6
  • 4
  • 2
  • Tagged with
  • 151
  • 116
  • 33
  • 24
  • 16
  • 16
  • 16
  • 14
  • 12
  • 11
  • 11
  • 11
  • 10
  • 10
  • 9
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
81

Combination 111In and 177Lu –Dotatoc and Vaccinia Virus Oncolytic Therapy for SSTR2-positive Tumors

Akinlolu, Olayinka 14 December 2009 (has links)
Radiolabeled somatostatin analogues based on octreotide have proven useful in the management of somatostatin receptor subtype 2 (sstr2)-positive tumours in clinical trials. The aim was to compare the potency and evaluate the combination of 111In- and 177Lu-DOTATOC with a double-deleted version of vaccinia virus (ddVV), an oncolytic virus for inhibiting the growth of sstr2-expressing human embryonic kidney (HEK-293) cells or MC-38 murine colon cancer cells grown as monolayers or as spheroids. Cytotoxicity studies were carried out using ddVV, 111In-DOTATOC and 177Lu-DOTATOC, individually or in combination on MC-38 spheroids, HEK-293 cells and spheroids. HEK-293 cell growth in spheroids was reduced to 17.2 ± 4.9% and 26.5 ± 6.3 % with 111In-DOTATOC and 177Lu-DOTATOC alone and 13.1 ± 7.1% and 0% in combination, respectively. MC-38 spheroids showed greater toxicity in combination treatment. Combination of ddVV with 111In- or 177Lu-DOTATOC is only advantageous in monolayer culture. No advantage was observed in spheroid models.
82

Combination 111In and 177Lu –Dotatoc and Vaccinia Virus Oncolytic Therapy for SSTR2-positive Tumors

Akinlolu, Olayinka 14 December 2009 (has links)
Radiolabeled somatostatin analogues based on octreotide have proven useful in the management of somatostatin receptor subtype 2 (sstr2)-positive tumours in clinical trials. The aim was to compare the potency and evaluate the combination of 111In- and 177Lu-DOTATOC with a double-deleted version of vaccinia virus (ddVV), an oncolytic virus for inhibiting the growth of sstr2-expressing human embryonic kidney (HEK-293) cells or MC-38 murine colon cancer cells grown as monolayers or as spheroids. Cytotoxicity studies were carried out using ddVV, 111In-DOTATOC and 177Lu-DOTATOC, individually or in combination on MC-38 spheroids, HEK-293 cells and spheroids. HEK-293 cell growth in spheroids was reduced to 17.2 ± 4.9% and 26.5 ± 6.3 % with 111In-DOTATOC and 177Lu-DOTATOC alone and 13.1 ± 7.1% and 0% in combination, respectively. MC-38 spheroids showed greater toxicity in combination treatment. Combination of ddVV with 111In- or 177Lu-DOTATOC is only advantageous in monolayer culture. No advantage was observed in spheroid models.
83

Proteolytic maturation of vaccinia virus structural proteins

VanSlyke, Judy K. 05 November 1992 (has links)
Vaccinia virus (VV) is a large DNA virus belonging to the Orthopoxvirus family. The viral replicative life cycle takes place solely within the cytoplasm of a mammalian host cell. The VV genome contains 196 open reading frames which are expressed in a highly regulated and temporal fashion in order to bring about the production of a mature virion. In the process of viral replication many VV proteins are synthesized that require posttranslational modifications to become functional. A few of these modifications include, glycosylation, ADP-ribosylation, phosphorylation, fatty acid acylation, and proteolytic processing. This last modification is especially important with regard to the structural proteins of the virus in that they undergo prysis for an infectious virus particle to be formed, a common theme in viral systems. In order to understand these events in more detail, three abundant virion protein constituents 4a, 4b, and 25K were chosen as models for study. The three main questions we wanted to answer were: Is there a cleavage consensus site within the precursors, what protease(s) and/or factors are necessary for the process, and how are the events regulated in vivo? Our approach included development of specific immunological reagents to identify cleavage products as well as to show where these core proteins are located during virion assembly. We have subsequently identified cleavage products by N-terminal microsequence from each of the three structural proteins and this information has elucidated a putative cleavage consensus site of Ala-Gly- X, where cleavage is proposed to take place between the Gly and X and X is usually an aliphatic residue. The immunological reagents were used in conjunction with immunofluorescent and immunogold labeling analyses to identify the location of these core proteins during virion assembly. Core proteins were localized to the virosomes in VV infected cells, to the viroplasm of immature virus particles, and to the center of mature virions. Precursor specific antiserum indicated that the larger molecular weight precursors of core proteins are within immature virions as well. From these results the following conclusions can be made. Identification of a putative cleavage consensus site suggests that proteolytic processing is an endoproteolytic event. The observation that precursor structural proteins were found within immature particles indicates that the proteinase responsible for cleavage is also present. The fact that assembly has to occur before proteolytic processing of VV structural proteins suggests that the cleavage events are dependent upon a specific core protein conformation. However the nature of this conformational requirement is not known. Further research is underway to develop a full understanding of the proteolytic events during virion morphogensis. / Graduation date: 1993
84

Oncolytic therapy with vaccinia virus GLV-1h68 comparative microarray analysis of infected xenografts and human tumor cell lines

Worschech, Andrea. Unknown Date (has links)
Univ., Diss., 2010--Würzburg.
85

Characterization of temperature sensitive vaccinia virus mutants in the a3l and e6r complementation groups

Strahl, Audra Lynne. January 2004 (has links)
Thesis (M.S.)--University of Florida, 2004. / Typescript. Title from title page of source document. Document formatted into pages; contains 59 pages. Includes Vita. Includes bibliographical references.
86

An In Vitro Selected Sequence Capable of Ultrahigh Transgene Expression in Vaccinia Virus Infected Cells

January 2012 (has links)
abstract: Recombinant protein expression is essential to biotechnology and molecular medicine, but facile methods for obtaining significant quantities of folded and functional protein in mammalian cell culture have been lacking. Here I describe a novel 37-nucleotide in vitro selected sequence that promotes unusually high transgene expression in a vaccinia driven cytoplasmic expression system. Vectors carrying this sequence in a monocistronic reporter plasmid produce >1,000-fold more protein than equivalent vectors with conventional vaccinia promoters. Initial mechanistic studies indicate that high protein expression results from dual activity that impacts both transcription and translation. I suggest that this motif represents a powerful new tool in vaccinia-based protein expression and vaccine development technology. / Dissertation/Thesis / M.S. Biochemistry 2012
87

Enhancing Oncolytic Virotherapy Using Functional Genomic Screening

Allan, Kristina Jean 24 July 2018 (has links)
No description available.
88

To Explode or to Implode: How Cells Decide Between Apoptosis and Necroptosis Following Viral or Chemical Stress

January 2018 (has links)
abstract: Cell death is a powerful tool through which organisms can inhibit the spread of viruses by preventing their replication. In this work, I used viral and chemical stressors to elucidate the mechanisms by which one anti-viral system might be activated over another, focusing on the programmable death pathway necroptosis and Protein Kinase R (PKR). PKR can detect viral dsRNA and trigger antiviral effects such as cessation of translation and induction of programmed death. Necroptosis is a rapid cellular death that can be induced via sensors such as DNA-dependent activator of IFN-regulatory factors (DAI), also known as Z-DNA-binding protein 1 (ZBP1). DAI contains a Z-form nucleic acid (ZNA) binding domain. E3, the primary vaccinia virus (VACV) interferon resistance protein, contains a similar domain in its amino terminus. We have previously reported this domain to be necessary for the inhibition of both PKR activation and DAI/ZBP1-mediated necroptosis. Monkeypox virus is a reemerging human pathogen. Despite a partial amino-terminal deletion in its E3 homolog, it does not activate PKR. In chapter 2, I show that MPXV produces less dsRNA than VACV, which could explain how the virus avoids activating PKR. The amino-terminus of vaccinia is associated with ZNA binding, inhibition of PKR, and inhibition of necroptosis. To determine the roles of PKR inhibition and ZNA binding in necroptosis inhibition, I characterized the VACV mutants Za(ADAR1)-E3, which binds ZNA but does not inhibit PKR, and E3:Y48A, which cannot bind ZNA. I found that while Za(ADAR1)-E3 fails to induce necroptosis, E3:Y48A does not activate PKR but does induce necroptosis. This suggests that Z-form nucleic acid binding is not necessary for vaccinia E3-mediated inhibition of PKR, nor is the inhibition of PKR sufficient for the inhibition of necroptosis. Finally, all known ZNA-binding proteins have immune functions and home to stress granules. I asked if stress granule formation alone could lead to necroptosis. I found that in L929 cells sodium arsenite, a known inducer of stress granules, could trigger DAI-dependent necroptosis. This suggests that DAI/ZBP1 is not necessarily a sensor of viral ligands but perhaps is a sensor of stress signals brought about by infection. / Dissertation/Thesis / Doctoral Dissertation Biological Design 2018
89

Comparaison des propriétés antiapoptotiques de quatre protéines du virus de la vaccine en isolement et au cours de l’infection virale. / Comparison of the anti-apoptotic properties of 4 vaccinia virus proteins in isolation and during viral infection

Veyer, David 05 December 2014 (has links)
L’apoptose, mort cellulaire observée suite à l’activation des caspases effectrices, est un moyen de défense contre les pathogènes, en particulier les virus. Le virus de la vaccine (VACV) est un virus contenant un grand génome à ADN codant pour environ 200 protéines, dont plusieurs inhibent l’apoptose. Cette apparente redondance fonctionnelle complique l’étude des protéines antiapoptotiques du virus dans un contexte d’infection virale. Dans ce travail, nous comparerons les propriétés antiapoptotiques des protéines B13, F1, GAAP et N1 de VACV. Cette comparaison sera établie dans un premier temps en dehors de toute infection virale. En utilisant des vecteurs lentiviraux, nous avons obtenu des lignées cellulaires stables (U2-OS) exprimant ces protéines en isolation. Nous avons alors pu tester les capacités antiapoptotiques de ces protéines en réponse à des stimuli provoquant l’apoptose extrinsèque et intrinsèque. Les résultats ont montré que B13 était la plus puissante molécule inhibitrice de l’apoptose intrinsèque et qu’elle était la seule à inhiber l’apoptose extrinsèque. Ensuite nous avons tiré avantage d’un virus de la vaccine déficient (vv811) qui ne possède aucune de ces protéines antiapoptotiques, capable à lui seul d’induire l’apoptose, en l’absence de toute autre stimulus. En infectant nos lignées cellulaires exprimant les molécules in trans avec vv811, nous avons pu montrer que B13 inhibait cette apoptose induite par le virus beaucoup plus efficacement que F1. GAAP et N1 dans ce contexte n’ont pas démontré de propriétés antiapoptotiques. Enfin, nous avons construit par mutagénèse des virus vv811 recombinants exprimant les molécules étudiées in cis. Suite à l’infection par ces virus de cellules U2-OS et Hela, B13, de nouveau, et F1 ont montré des capacités d’inhibition importantes de l’apoptose. L’action de GAAP s’est révélée dépendante du type cellulaire et N1 n’a pas pu inhiber l’apoptose induite par ce virus déficient dans aucune des cellules testées. En utilisant ces différentes approches, nous avons pu nous affranchir des problèmes de redondance et comparer 4 molécules antiapoptotiques du virus de la vaccine, y compris dans un contexte d’infection virale. Les résultats ont confirmé que toutes les protéines étudiées possédaient des propriétés antiapoptiques et ont clairement montré que B13 était la plus puissante / Apoptosis, which occurs following activation of effector caspases, can restrict the replication of intracellular pathogens, especially viruses. Vaccinia virus (VACV) is a large dsDNA virus encoding approximately 200 proteins, several of which inhibit apoptosis. This redundancy of viral anti-apoptotic proteins complicates the study of these proteins in the context of viral infection. Here a comparative study of the anti-apoptotic proteins B13, F1, GAAP and N1 with and without virus infection is presented. Firstly, using lentiviral constructs, we generated transduced cell lines expressing the anti-apoptotic proteins in isolation and we analysed their ability to protect against extrinsic and intrinsic apoptosis induced by different drugs. In that context B13 was the most potent inhibitor of intrinsic apoptosis and the only protein to inhibit both extrinsic and intrinsic apoptosis. We then used a deficient VACV strain, vv811, that lacks the genes coding for the four anti-apoptotic proteins. Infection with vv811 can induce apoptosis without the need for any other stimulus. After vv811 infection of cell lines expressing the anti-apoptotic proteins in trans, B13 and to a lesser extent F1, inhibited apoptosis. Finally, we introduced each gene separately into vv811 by genetic recombination. Using these recombinant viruses to induce apoptosis, B13 and F1 were very potent inhibitors. The protection conferred by GAAP was cell type dependant and N1 failed to protect any of the tested cells from the virus induced apoptosis. Using these different approaches, we have been able to overcome the redundancy issue to compare 4 anti-apoptotic proteins from VACV, including in the context of viral infection. The results illustrate that vv811 is a useful tool to determine the role of VACV anti-apoptotic proteins during infection and that whilst all of these proteins have some anti-apoptotic activity, B13 is most potent.
90

Vaccinia and Dengue Viruses: Exploring Current Fundamental Issues of Memory T Cells and Utilizing Comparative Quantitative Immunology to Compare Correlates of Protection Following Smallpox Immunization

Ostrout, Nicholas D. 05 April 2008 (has links)
No description available.

Page generated in 0.1028 seconds